Viking Therapeutics expects to release early-stage data for its lead weight-loss drug, VK2735, this quarter. The upcoming results evaluate less-frequent and oral dosing schedules. The company plans to launch late-stage trials for an oral pill version of the drug in the fourth quarter.
Bank of New York Mellon Corp reported a new position in Viking Therapeutics on September 1, 2026. The firm acquired 407,840 shares in the second quarter, valued at approximately $15.91 million. Quantitative Investment Management LLC also recently established a new stake in the company.
Analyst sentiment remains largely positive. A majority of market experts currently rate the stock as a Buy.